Total
0
Shares
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham - The Market Herald
CEO, James Graham
Source: Finance News Network
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Recce Pharmaceuticals (RCE) has begun the process to dual list on the Frankfurt Stock Exchange (FSE)
  • The company has appointed Deutsche Gesellschaft Für Wertpapieranalyse (DGWA) as its investor and corporate relations advisor in Europe
  • DGWA will engage prospective investors and drive awareness of Recce's products
  • Dual listing on the FSE will give Recce exposure to multiple retail and institutional investors in the European Union
  • The company will keep the market updated as the listing progresses
  • Shares in Recce are steady on the market and are trading at $1.05 per share

Recce Pharmaceuticals (RCE) has begun the process to dual list on the Frankfurt Stock Exchange (FSE).

The FSE is the tenth-largest stock exchange in the world, third-largest in Europe and is owned and operated by Deutsche Börse AG and Börse Frankfurt Zertifikate AG.

Recce has appointed Deutsche Gesellschaft Für Wertpapieranalyse (DGWA) as its investor and corporate relations advisor in Europe.

DGWA will engage prospective investors and drive awareness of Recce's products.

"We are excited to support Recce in engagement with European investors and opportunities to expand its infectious disease programs," DGWA CEO Stefan Müller said.

Dual listing on the FSE will give Recce exposure to multiple retail and institutional investors in the European Union.

"Dual listing on the FSE enables Recce to broaden its exposure to European investors," Chairman Dr John Prendergast said.

"The company considers that it meets the requirement necessary to dual list on the FSE and will provide updates on its application process," he added.

Recce expects further developments regarding the listing process will be completed in the upcoming weeks.

Shares in Recce are steady on the market and are trading at $1.05 each.

RCE by the numbers
More From The Market Herald
Merchant House International (ASX:AHI) - Founder and Chairwoman, Loretta Lee - The Market Herald

" Merchant House International (ASX:MHI) surges 166pc on subsidiary sale

Citing subdued economic conditions in China, Merchant House International (MHI) has decided to sell its subsidiary, Carsan Manufacturing.
Anatara Lifesciences (ASX:ANR) - CEO, Steven Lydeamore - The Market Herald

" Anatara Lifesciences (ASX:ANR) secures patent for animal health product

Anatara Lifesciences (ANR) has been granted an Australian patent covering the formulation for its animal health product, Detach.
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham - The Market Herald

" Recce Pharmaceuticals (ASX:RCE) advances new clinical trials

Recce Pharmaceuticals (RCE) is close to commencing human clinical trials for its topical burns treatment, RECCE 327.
Mayne Pharma (ASX:MYX) - CEO, Scott Richards - The Market Herald

" Mayne Pharma’s (ASX:MYX) oral contraceptive receives FDA approval

Mayne Pharma (MYX) and Mithra Pharmaceuticals have received approval for its combined oral contraceptive Nextstellis from the U.S. Food and Drug Administration (FDA).